MCID: CHL010
MIFTS: 43

Childhood Kidney Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Childhood Kidney Cell Carcinoma

MalaCards integrated aliases for Childhood Kidney Cell Carcinoma:

Name: Childhood Kidney Cell Carcinoma 12 15
Pediatric Renal Cell Carcinoma 12
Childhood Renal Cell Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4454
NCIt 50 C6568
UMLS 73 C1333001

Summaries for Childhood Kidney Cell Carcinoma

MalaCards based summary : Childhood Kidney Cell Carcinoma, also known as pediatric renal cell carcinoma, is related to renal cell carcinoma, nonpapillary and central nervous system mesenchymal non-meningothelial tumor, and has symptoms including flank pain An important gene associated with Childhood Kidney Cell Carcinoma is TPM3 (Tropomyosin 3), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Gemcitabine and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and brain, and related phenotypes are cellular and mortality/aging

Related Diseases for Childhood Kidney Cell Carcinoma

Diseases related to Childhood Kidney Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 28.6 MITF PAX2 PRCC TFE3 TFEB TSC2
2 central nervous system mesenchymal non-meningothelial tumor 10.7 FOXO1 PAX3
3 waardenburg syndrome, type 1 10.6 MITF PAX3
4 appendix carcinoid tumor 10.6 MLH1 MSH2
5 adenosquamous colon carcinoma 10.6 MLH1 MSH2
6 waardenburg syndrome, type 2a 10.6 MITF TFE3
7 sebaceous adenoma 10.6 MLH1 MSH2
8 tietz albinism-deafness syndrome 10.6 MITF PAX3
9 lower lip cancer 10.6 MLH1 MSH2
10 pleomorphic rhabdomyosarcoma 10.5 FOXO1 PAX3
11 cochlear disease 10.5 MITF PAX3
12 anal fistula 10.5 MLH1 MSH2
13 clear cell papillary renal cell carcinoma 10.5 MITF TFE3
14 kidney benign neoplasm 10.4 PAX2 TSC2
15 rhabdomyosarcoma 2 10.4 ALK FOXO1 PAX3
16 mismatch repair cancer syndrome 10.4 MLH1 MSH2 PAX3
17 skeletal muscle cancer 10.3 FOXO1 PAX3 TFE3
18 autosomal genetic disease 10.3 MLH1 MSH2 TSC2
19 autosomal dominant disease 10.3 MLH1 MSH2 PAX3
20 waardenburg's syndrome 10.3 MITF PAX3 TFE3
21 lung papillary adenocarcinoma 10.1 ALK EML4
22 rhabdomyosarcoma 10.1 ALK FOXO1 MSH2 PAX3
23 inflammatory myofibroblastic tumor 10.0 ALK EML4 TPM3
24 renal cell carcinoma, papillary, 1 10.0 MITF PRCC TFE3
25 alveolar soft part sarcoma 10.0 ASPSCR1 MLH1 TFE3
26 xanthogranulomatous pyelonephritis 10.0 ALK PRCC TFE3
27 melanocytic nevus syndrome, congenital 9.9 MLH1 MSH2
28 lung adenoid cystic carcinoma 9.8 ALK EML4
29 muscle cancer 9.8 ASPSCR1 FOXO1 PAX3 TFE3
30 mucinous tubular and spindle renal cell carcinoma 9.8 PRCC TFE3
31 microphthalmia 9.7 MITF PAX2 PAX3 TFE3 TFEB
32 renal cell carcinoma, xp11-associated 9.3 ASPSCR1 PRCC TFE3 TFEB

Graphical network of the top 20 diseases related to Childhood Kidney Cell Carcinoma:



Diseases related to Childhood Kidney Cell Carcinoma

Symptoms & Phenotypes for Childhood Kidney Cell Carcinoma

UMLS symptoms related to Childhood Kidney Cell Carcinoma:


flank pain

MGI Mouse Phenotypes related to Childhood Kidney Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 F3 FOXO1 GPX7 MITF MLH1 MSH2
2 mortality/aging MP:0010768 10.1 MSH2 PAX2 PAX3 TFE3 TFEB TPM3
3 integument MP:0010771 10.02 ALK F3 FOXO1 MITF MLH1 MSH2
4 embryo MP:0005380 9.97 F3 FOXO1 MITF PAX2 PAX3 TFEB
5 neoplasm MP:0002006 9.76 ALK F3 FOXO1 GPX7 MLH1 MSH2
6 pigmentation MP:0001186 9.43 ALK MITF PAX2 PAX3 TFE3 TFEB
7 vision/eye MP:0005391 9.23 TFEB ALK F3 MITF MLH1 PAX2

Drugs & Therapeutics for Childhood Kidney Cell Carcinoma

Drugs for Childhood Kidney Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
2
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 284461-73-0 216239 406563
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
4
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
5
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
6
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
7
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
8
Zoledronic acid Approved Phase 4,Phase 1,Phase 2 118072-93-8 68740
9
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
10
nivolumab Approved Phase 4,Phase 3,Phase 1,Phase 2 946414-94-4
11
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 98-92-0 936
12
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 59-67-6 938
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
14
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
15 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 interferons Phase 4,Phase 3,Phase 2,Phase 1
18 Micronutrients Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
19 Neurotransmitter Agents Phase 4,Phase 2
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Nicotinic Acids Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
22 Trace Elements Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
23 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Vitamins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39
Erlotinib Hydrochloride Phase 4,Phase 2,Phase 1 183319-69-9 176871
40 Central Nervous System Depressants Phase 4,Phase 3
41 Adjuvants, Anesthesia Phase 4,Phase 3
42 Central Nervous System Stimulants Phase 4
43 GABA Agents Phase 4
44 GABA Modulators Phase 4
45 Anesthetics Phase 4,Phase 3
46 Anesthetics, General Phase 4,Phase 3
47 Anesthetics, Intravenous Phase 4,Phase 3
48 Tranquilizing Agents Phase 4
49 Diphosphonates Phase 4,Phase 1,Phase 2
50 Anti-Anxiety Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 536)
# Name Status NCT ID Phase Drugs
1 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
2 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
3 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00006864 Phase 4
4 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
5 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
6 Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
7 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) Terminated NCT02338570 Phase 4 Everolimus
8 Exercise for Patients With Renal Cell Cancer Receiving Sunitinib Unknown status NCT00869011 Phase 3
9 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed NCT00678392 Phase 3 Axitinib (AG-013736);Sorafenib
10 Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer Completed NCT00073307 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
11 A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
12 Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Completed NCT00387764 Phase 3 pazopanib
13 A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer Completed NCT00375674 Phase 3 Sunitinib malate
14 Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma. Completed NCT00502034 Phase 3 Interferon Alfa-2a;Interleukin-2
15 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Completed NCT01223027 Phase 3 Dovitinib;Sorafenib
16 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed NCT00326898 Phase 3 Sorafenib;Sunitinib
17 Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer Completed NCT00416429 Phase 3 medroxyprogesterone
18 Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer Completed NCT00416871 Phase 3
19 Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
20 AE-941 in Treating Patients With Metastatic Kidney Cancer Completed NCT00005995 Phase 3 shark cartilage extract AE-941
21 Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Completed NCT00018941 Phase 3
22 Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer Completed NCT00002473 Phase 3
23 Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer Completed NCT00053807 Phase 3 fluorouracil
24 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00005966 Phase 3 thalidomide
25 Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer Completed NCT00053820 Phase 3 fluorouracil
26 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib
27 An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
28 Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) Completed NCT00072046 Phase 3
29 Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer Completed NCT00003126 Phase 3 Interleukin-2
30 Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer Completed NCT00087022 Phase 3
31 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3 sorafenib tosylate
32 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases Completed NCT00540969 Phase 3
34 ImmuniCell® in Patients With Advanced Cancers Recruiting NCT02459067 Phase 2, Phase 3
35 CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma Recruiting NCT03095040 Phase 2, Phase 3 CM082 combined with everolimus;CM082;Everolimus
36 Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib Recruiting NCT03013946 Phase 3
37 Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy Recruiting NCT03055013 Phase 3
38 Savolitinib vs. Sunitinib in MET-driven PRCC Recruiting NCT03091192 Phase 3 Savolitinib;Sunitinib
39 Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer Active, not recruiting NCT00920816 Phase 3 Axitinib (AG-013736);Sorafenib
40 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) Active, not recruiting NCT02684006 Phase 3 Avelumab (MSB0010718C);Axitinib (AG-013736);Sunitinib
41 A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma Active, not recruiting NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
42 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Active, not recruiting NCT02231749 Phase 3 Sunitinib
43 Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer Active, not recruiting NCT01099423 Phase 3
44 Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Active, not recruiting NCT01575548 Phase 3 Pazopanib Hydrochloride
45 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3 Everolimus
46 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3 everolimus
47 Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma Terminated NCT00311467 Phase 3 Capecitabine, Interferon, Interleukin
48 Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients Terminated NCT01599754 Phase 3 Axitinib;Placebo
49 Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma Withdrawn NCT00061178 Phase 3 rhuMAb VEGF (Bevacizumab)
50 Temsirolimus-RCC-imaging Unknown status NCT01246817 Phase 2 Temsirolimus

Search NIH Clinical Center for Childhood Kidney Cell Carcinoma

Genetic Tests for Childhood Kidney Cell Carcinoma

Anatomical Context for Childhood Kidney Cell Carcinoma

MalaCards organs/tissues related to Childhood Kidney Cell Carcinoma:

41
Kidney, Lung, Brain, Breast, Endothelial, Bone, Liver

Publications for Childhood Kidney Cell Carcinoma

Articles related to Childhood Kidney Cell Carcinoma:

# Title Authors Year
1
Biological characteristics of pediatric renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions. ( 24726108 )
2014
2
Persistent complete response after single-agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. ( 22995920 )
2013
3
Pediatric renal cell carcinoma. ( 19443274 )
2009
4
Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family. ( 16880148 )
2006
5
Pediatric renal cell carcinomas with Xp11.2 rearrangements are immunoreactive for hMLH1 and hMSH2 proteins. ( 16328670 )
2005

Variations for Childhood Kidney Cell Carcinoma

Cosmic variations for Childhood Kidney Cell Carcinoma:

9
(show top 50) (show all 242)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma c.563G>C p.G188A 23:123886225-123886225 8
2 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma c.353T>C p.L118P 3:10146526-10146526 8
3 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma c.548C>A p.S183* 3:10149871-10149871 8
4 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma c.256C>T p.P86S 3:10142103-10142103 8
5 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma c.292T>G p.Y98D 3:10142139-10142139 8
6 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma c.245G>C p.R82P 3:10142092-10142092 8
7 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma c.266T>A p.L89H 3:10142113-10142113 8
8 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 8
9 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma c.234T>G p.N78K 3:10142081-10142081 8
10 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma c.500G>A p.R167Q 3:10149823-10149823 8
11 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma c.482G>A p.R161Q 3:10149805-10149805 8
12 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma c.341-2A>T p.? 3:10146512-10146512 8
13 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma c.217C>T p.Q73* 3:10142064-10142064 8
14 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 8
15 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma c.541G>A p.V181M 16:2055461-2055461 8
16 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.2287C>T p.Q763* 9:132902709-132902709 8
17 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.1001C>A p.S334* 9:132911481-132911481 8
18 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma c.508+1G>T p.? 9:132923347-132923347 8
19 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 8
20 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 8
21 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma c.374C>G p.T125R 17:7675995-7675995 8
22 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma c.404G>T p.C135F 17:7675208-7675208 8
23 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma c.738G>A p.M246I 17:7674225-7674225 8
24 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma c.97-2A>C p.? 17:7676274-7676274 8
25 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma c.673-1G>T p.? 17:7674291-7674291 8
26 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma c.510G>T p.W170C 12:114681026-114681026 8
27 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2096+1G>A p.? 23:124065947-124065947 8
28 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.1348A>T p.R450* 23:124057909-124057909 8
29 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma c.2860C>T p.R954C 23:124081464-124081464 8
30 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma c.265T>G p.L89V 17:49619321-49619321 8
31 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.987-2A>T p.? 22:23833570-23833570 8
32 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma c.1130G>A p.R377H 22:23834152-23834152 8
33 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma c.3575G>A p.R1192H 19:11033318-11033318 8
34 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.863C>A p.S288* 3:47122264-47122264 8
35 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.4736C>G p.S1579* 3:47062211-47062211 8
36 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.3266G>A p.R1089Q 3:47106061-47106061 8
37 COSM4794860 SETD2 kidney,NS,carcinoma,renal cell carcinoma c.5922+1G>A p.? 3:47019759-47019759 8
38 COSM26594 RNF144A kidney,NS,carcinoma,renal cell c.410C>T p.A137V 2:7020581-7020581 8
39 COSM26987 RGS7 kidney,NS,carcinoma,renal cell c.169T>C p.F57L 1:241098672-241098672 8
40 COSM6925125 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.179C>A p.S60* 23:47169476-47169476 8
41 COSM6922201 RBM10 kidney,NS,carcinoma,renal cell carcinoma c.299G>C p.G100A 23:47171125-47171125 8
42 COSM26614 RABGAP1 kidney,NS,carcinoma,renal cell c.1533T>A p.H511Q 9:123020414-123020414 8
43 COSM30530 PTPN22 kidney,NS,carcinoma,renal cell c.209G>C p.R70P 1:113859066-113859066 8
44 COSM6947629 PTCH1 kidney,NS,carcinoma,renal cell carcinoma c.3616C>T p.R1206C 9:95449257-95449257 8
45 COSM6927541 PRKN kidney,NS,carcinoma,renal cell carcinoma c.629T>G p.F210C 6:161973407-161973407 8
46 COSM6913448 POLE kidney,NS,carcinoma,renal cell carcinoma c.4735C>T p.R1579C 12:132642723-132642723 8
47 COSM6972882 PMS1 kidney,NS,carcinoma,renal cell carcinoma c.572T>A p.V191E 2:189818170-189818170 8
48 COSM6923488 PIM1 kidney,NS,carcinoma,renal cell carcinoma c.101T>A p.L34Q 6:37170791-37170791 8
49 COSM6969911 PIK3CG kidney,NS,carcinoma,renal cell carcinoma c.2039T>A p.F680Y 7:106872580-106872580 8
50 COSM763 PIK3CA kidney,NS,carcinoma,renal cell carcinoma c.1633G>A p.E545K 3:179218303-179218303 8

Expression for Childhood Kidney Cell Carcinoma

Search GEO for disease gene expression data for Childhood Kidney Cell Carcinoma.

Pathways for Childhood Kidney Cell Carcinoma

GO Terms for Childhood Kidney Cell Carcinoma

Cellular components related to Childhood Kidney Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.61 ASPSCR1 FOXO1 MITF MLH1 MSH2 PAX3
2 mismatch repair complex GO:0032300 8.62 MLH1 MSH2

Biological processes related to Childhood Kidney Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 FOXO1 MITF PAX2 PAX3 TFE3 TFEB
2 humoral immune response GO:0006959 9.54 MITF TFE3 TFEB
3 somatic hypermutation of immunoglobulin genes GO:0016446 9.48 MLH1 MSH2
4 regulation of osteoclast differentiation GO:0045670 9.46 MITF TFE3
5 isotype switching GO:0045190 9.43 MLH1 MSH2
6 positive regulation of transcription, DNA-templated GO:0045893 9.43 FOXO1 MITF PAX2 PAX3 TFE3 TFEB
7 positive regulation of isotype switching to IgG isotypes GO:0048304 9.4 MLH1 MSH2
8 protein kinase B signaling GO:0043491 9.33 FOXO1 PAX2 TSC2
9 positive regulation of isotype switching to IgA isotypes GO:0048298 9.32 MLH1 MSH2
10 somatic recombination of immunoglobulin gene segments GO:0016447 9.26 MLH1 MSH2
11 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MLH1 MSH2

Molecular functions related to Childhood Kidney Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 ALK ASPSCR1 EML4 F3 FOXO1 GPX7
2 mismatched DNA binding GO:0030983 9.16 MLH1 MSH2
3 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH2

Sources for Childhood Kidney Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....